tax notes international - Tuck School of Business - Dartmouth College
tax notes international - Tuck School of Business - Dartmouth College
tax notes international - Tuck School of Business - Dartmouth College
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
SPECIAL REPORTS<br />
The second exception is that the differential is due<br />
to extraordinary events beyond the control <strong>of</strong> the controlled<br />
participants that could not reasonably have been<br />
anticipated as <strong>of</strong> the date <strong>of</strong> the trigger PCT.<br />
The third exception is that the periodic trigger<br />
would not have occurred had the PCT payer’s divisional<br />
pr<strong>of</strong>its or losses used to calculate its present<br />
value <strong>of</strong> total pr<strong>of</strong>its (PVTP) excluded those pr<strong>of</strong>its or<br />
losses attributable to the PCT payer’s routine contributions<br />
to its exploitation <strong>of</strong> the cost-shared intangibles,<br />
attributable to its operating cost contributions, and attributable<br />
to its nonroutine contributions to the CSA<br />
activity.<br />
In an important narrowing,<br />
the temporary regulations<br />
provide that a periodic<br />
trigger occurs if the AERR<br />
falls outside the PRRR <strong>of</strong><br />
between 0.667 and 1.5.<br />
The fourth exception is that the periodic trigger<br />
would not have occurred had the divisional pr<strong>of</strong>its or<br />
losses <strong>of</strong> the PCT payer used to calculate its PVTP<br />
included its reasonably anticipated divisional pr<strong>of</strong>its or<br />
losses after the adjustment year from the CSA activity,<br />
including its routine contributions, its operating cost<br />
contributions, and its nonroutine contributions to that<br />
activity, and had the cost contributions and PCT payments<br />
<strong>of</strong> the PCT payer used to calculate its PVI<br />
(present value <strong>of</strong> the PCT payer’s investment at the<br />
start date) included its reasonably anticipated cost contributions<br />
and PCT payments after the adjustment year.<br />
Also, a periodic trigger will not be deemed to have<br />
occurred in any year subsequent to the 10-year period<br />
beginning with the first <strong>tax</strong> year in which there is substantial<br />
exploitation <strong>of</strong> the cost-shared intangibles resulting<br />
from the CSA, if the AERR is within the<br />
PRRR for each year <strong>of</strong> the 10-year period. It also will<br />
not be deemed to have occurred in any year <strong>of</strong> the<br />
five-year period beginning with the first <strong>tax</strong> year in<br />
which there is exploitation <strong>of</strong> the cost-shared intangibles<br />
resulting from the CSA if the AERR falls below<br />
the lower bound <strong>of</strong> the PRRR.<br />
The IRS and Treasury intend to issue by revenue<br />
procedure separate published guidance that provides an<br />
exception to periodic adjustments in the context <strong>of</strong> an<br />
advance pricing agreement. The guidance would provide<br />
that no periodic adjustments will be made in any<br />
year based on a trigger PCT that is a covered transaction<br />
under the APA. An APA process generally is contemporaneous<br />
with the <strong>tax</strong>payer’s original transactions<br />
and involves transparency concerning a <strong>tax</strong>payer’s upfront<br />
efforts to conform to the arm’s-length standard.<br />
Treatment <strong>of</strong> Payments<br />
CST payments generally will be considered the<br />
payer’s cost <strong>of</strong> developing intangibles at the location<br />
where the development is conducted. For these purposes,<br />
IDCs borne directly by a controlled participant<br />
that are deductible are deemed to be reduced to the<br />
extent <strong>of</strong> any CST payments owed to it by other controlled<br />
participants under the CSA.<br />
The PCT payer’s payment is deemed to be reduced<br />
to the extent <strong>of</strong> any payments owed to it from other<br />
controlled participants. PCT payments will be characterized<br />
consistently with the <strong>tax</strong>payer’s designation <strong>of</strong><br />
the type <strong>of</strong> transaction. Depending on the designation,<br />
the payments will be treated as either consideration for<br />
a transfer <strong>of</strong> an interest in intangible property or for<br />
services.<br />
Administrative Requirements<br />
Temp. Treas. reg. section 1.482-7T(k) contains the<br />
CSA administrative requirements. There are four main<br />
sections: contractual; documentation; accounting; and<br />
reporting requirements. This section <strong>of</strong> the temporary<br />
regulations is lengthy.<br />
The contractual rules are important. CSA agreements<br />
already in effect will need to be modified by<br />
July 6, 2009, by integrating those rules with the transition<br />
rules in temp. Treas. reg. section 1.482-7T(m). A<br />
CSA statement also will need to be filed by September<br />
2, 2009.<br />
Documentation is especially important under the<br />
temporary regulations. For example, careful analysis<br />
and documentation <strong>of</strong> discount rate choices could be<br />
very important. Also, the periodic adjustment trigger<br />
range is narrower for <strong>tax</strong>payers that fail to maintain<br />
adequate documentation.<br />
New Best Method Examples<br />
Example 13. USP and FS enter into a CSA to develop<br />
a new drug. Immediately before entering into the<br />
CSA, USP acquires Company X. X is engaged in research<br />
relevant to the product area, and its only significant<br />
resources and capabilities are its workforce and<br />
sole patent. The patent is associated with a compound<br />
that USP reasonably anticipates will contribute to developing<br />
the CSA product. The acquisition price<br />
method, based on the lump sum price paid by USP for<br />
Company X, is likely to provide a more reliable measure<br />
<strong>of</strong> an arm’s-length result than any other method.<br />
Example 14. Company X is a publicly traded U.S.<br />
company engaged in pharmaceutical research. Its only<br />
significant resources and capabilities are workforce and<br />
its sole patent. Company X has no marketable products.<br />
Company X enters into a CSA with FS, its newly<br />
formed foreign subsidiary, to develop a new drug. The<br />
new drug will be derived from the compound covered<br />
468 • FEBRUARY 2, 2009 TAX NOTES INTERNATIONAL<br />
(C) Tax Analysts 2009. All rights reserved. Tax Analysts does not claim copyright in any public domain or third party content.